August 3, 2025Open Access

Impact of SGLT2 Inhibitors in the Management of Diabetes and Heart Failure Comorbidity: A Review of Current Evidence

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Review shows SGLT2 inhibitors improve heart failure outcomes in diabetes patients, suggesting need for wider application.

SGLT2 inhibitors demonstrate superior efficacy in reducing heart failure risks compared to placebo in diabetes patients.
Clinical trials report significant cardioprotective benefits, reducing major adverse cardiovascular events effectively.
Higher rates of adverse effects such as hypoglycemia and infections occurred among patients receiving SGLT2 inhibitors.
Current research highlights a gap in understanding the comprehensive safety and efficacy of SGLT2 inhibitors in diverse populations.

Saheed Sanyaolu (2025) studied this question.

View Full Paper

Ask AI

Bookmark